JP3241610B2 - Pharmaceuticals containing bean tea extract as an active ingredient, and foods and cosmetics containing the same - Google Patents
Pharmaceuticals containing bean tea extract as an active ingredient, and foods and cosmetics containing the sameInfo
- Publication number
- JP3241610B2 JP3241610B2 JP26906896A JP26906896A JP3241610B2 JP 3241610 B2 JP3241610 B2 JP 3241610B2 JP 26906896 A JP26906896 A JP 26906896A JP 26906896 A JP26906896 A JP 26906896A JP 3241610 B2 JP3241610 B2 JP 3241610B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- hyaluronic acid
- tea extract
- tea
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000284 extract Substances 0.000 title claims description 67
- 239000002537 cosmetic Substances 0.000 title claims description 17
- 235000013305 food Nutrition 0.000 title claims description 15
- 244000046052 Phaseolus vulgaris Species 0.000 title claims description 14
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title claims description 14
- 239000004480 active ingredient Substances 0.000 title claims description 7
- 244000269722 Thea sinensis Species 0.000 title claims 4
- 239000003814 drug Substances 0.000 title description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 26
- 229920002674 hyaluronan Polymers 0.000 claims description 26
- 229960003160 hyaluronic acid Drugs 0.000 claims description 26
- 239000003112 inhibitor Substances 0.000 claims description 12
- 235000009508 confectionery Nutrition 0.000 claims description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 238000000354 decomposition reaction Methods 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 235000013353 coffee beverage Nutrition 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 235000014171 carbonated beverage Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000015243 ice cream Nutrition 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 235000011962 puddings Nutrition 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- 239000005862 Whey Substances 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 239000008278 cosmetic cream Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 235000014214 soft drink Nutrition 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims 2
- 235000013373 food additive Nutrition 0.000 claims 2
- 230000003779 hair growth Effects 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 235000019341 magnesium sulphate Nutrition 0.000 claims 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 229940034610 toothpaste Drugs 0.000 claims 1
- 241001122767 Theaceae Species 0.000 description 44
- 239000000203 mixture Substances 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 26
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229960002773 hyaluronidase Drugs 0.000 description 12
- -1 methanol and ethanol Chemical class 0.000 description 12
- 108010003272 Hyaluronate lyase Proteins 0.000 description 11
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 229960001340 histamine Drugs 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000003266 anti-allergic effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 7
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 6
- 239000000043 antiallergic agent Substances 0.000 description 6
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 235000021552 granulated sugar Nutrition 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229940010747 sodium hyaluronate Drugs 0.000 description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 102200004779 rs2232775 Human genes 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000220151 Saxifragaceae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920002055 compound 48/80 Polymers 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-BKJPEWSUSA-N N-acetyl-D-hexosamine Chemical compound CC(=O)NC1C(O)O[C@H](CO)C(O)C1O OVRNDRQMDRJTHS-BKJPEWSUSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 description 1
- 241001409321 Siraitia grosvenorii Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- YDCVUQVGJSAAKA-UHFFFAOYSA-N octadecanoic acid;prop-1-ene Chemical compound CC=C.CCCCCCCCCCCCCCCCCC(O)=O YDCVUQVGJSAAKA-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristoyl-sn-glycerol Natural products CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Jellies, Jams, And Syrups (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
- Dairy Products (AREA)
- Grain Derivatives (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、甜茶抽出物を有効成分
とする医薬に関し、更に詳細には、抗炎症、抗アレルギ
ーおよびヒアルロン酸の分解阻止作用を有する医薬なら
びにこれを含有する食品および化粧品に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a medicament comprising a tea extract as an active ingredient, and more particularly to a medicament having anti-inflammatory, anti-allergic and hyaluronic acid decomposition inhibitory activities, and food and cosmetics containing the same. About.
【0002】[0002]
【従来の技術】科学技術の発達に従い、多くの化合物が
合成され、種々の作用を有する医薬が見出されてきた。
例えば、抗炎症剤として、化学合成品を主に多数の薬物
が開発されてきた。そして、約100年前より、臨床に
用いられてきたアスピリンの作用点が、アラキドン酸よ
りプロスタグランジン(以下、「PG」と略す)の合成
に至る過程の初発酵素であるシクロオキシゲナーゼ阻害
にあることが解明されたことを契機として、インドメタ
シンなどの、同様の作用メカニズムによる強力な薬効を
有するものが開発されてきた。2. Description of the Related Art With the development of science and technology, many compounds have been synthesized, and drugs having various actions have been found.
For example, a large number of drugs have been developed mainly as chemically synthesized products as anti-inflammatory agents. The point of action of aspirin, which has been used clinically since about 100 years ago, lies in the inhibition of cyclooxygenase, the first enzyme in the process from arachidonic acid to the synthesis of prostaglandin (hereinafter abbreviated as "PG"). As a result, e.g., indomethacin, which has a strong pharmacological effect by a similar mechanism of action, has been developed.
【0003】また、抗アレルギー剤としては、ジソジウ
ムクロモグリケート(以下、「DSCG」と略す)など
の化学合成品が、アラキドン酸よりロイコトリエンを生
成させる5−リポキシゲナーゼの阻害剤としてはカフェ
ー酸を多量に含むヨモギ抽出物などが用いられている。[0003] Further, as an antiallergic agent, a chemically synthesized product such as disodium chromoglycate (hereinafter abbreviated as "DSCG") and caffeic acid as an inhibitor of 5-lipoxygenase which generates leukotriene from arachidonic acid are used. A mugwort extract containing a large amount is used.
【0004】以上は、いずれも医薬品の成分に関するも
のであるが、他方、抗炎症あるいは抗アレルギーに寄与
すると思われる食品素材も求められているが、羅漢果抽
出物などが伝承にのみ基づいて使用されているのが現状
である。 また、抗炎症あるいは抗アレルギー活性を有
する化粧品原料についても種々探索されているが、安全
かつ有望なものは未だ得られていない。[0004] The above all relate to the components of pharmaceuticals. On the other hand, food materials which are thought to contribute to anti-inflammatory or anti-allergy are also required. That is the current situation. In addition, various cosmetic raw materials having anti-inflammatory or anti-allergic activity have been searched for, but safe and promising ones have not yet been obtained.
【0005】一方、保湿剤として、微生物などに由来す
るヒアルロン酸が主に化粧品に配合されているが、最
近、ヒアルロン酸分解酵素であるヒアルロニダーゼに対
する阻害活性を1つの指標として、茶抽出液の抗アレル
ギー活性を評価しようとする試みが行われており(前田
有美恵ら:食衛誌、31巻、233−237頁、199
0)、ヒアルロニダーゼ阻害活性と抗アレルギー活性の
相関が示唆されている。On the other hand, hyaluronic acid derived from microorganisms or the like is mainly used in cosmetics as a humectant, but recently, the inhibitory activity against hyaluronidase, a hyaluronic acid-degrading enzyme, is used as an index to evaluate the antioxidant properties of tea extract. Attempts have been made to evaluate allergic activity (Yumie Maeda et al .: Food and Essays, Vol. 31, pp. 233-237, 199).
0), a correlation between hyaluronidase inhibitory activity and antiallergic activity has been suggested.
【0006】[0006]
【発明が解決しようとする課題】21世紀に向けて、疾
病の治療よりも予防の必要性が叫ばれている。 例え
ば、炎症やアレルギーは人体の持つ抵抗力の過剰反応と
考えられている側面もあるが、発病時の苦難を思うと
き、そのなんらかの予防措置が必要とされる。花粉症な
どのアレルギー疾患の最近の激増ぶりには、目を見張る
ばかりである。 元々は、寄生虫排除の目的で人体内に
備わっているIgEが、近年、人体の寄生虫保有の減少
と共に、アレルギーを起こす方に働いているためである
が、食物として脂肪、特にリノール酸を多く含むものの
摂取が増えている面も見逃すことが出来ない。 リノー
ル酸は生体内で容易にアラキドン酸に不飽和化され、そ
れから生ずるロイコトリエンがアレルギーの原因になる
からである。 社会が豊かになるにつれて、人体が寄生
虫を保有することの減少と脂肪摂取量の増加により、ア
レルギーは増える傾向にあるが、十分に有効な抗アレル
ギー剤は見出だされておらず、その開発は重要な課題で
ある。For the 21st century, the necessity of prevention rather than treatment of disease has been called for. For example, inflammation and allergies are considered to be an overreaction of the human body's resistance, but some precautionary measures are needed when suffering from onset. The recent surge in allergic diseases, such as hay fever, is only remarkable. Originally, IgE, which is present in the human body for the purpose of eliminating parasites, has recently been working on those who cause allergies along with a decrease in the number of parasites in the human body, but fats, especially linoleic acid, are used as food. We cannot overlook the fact that the intake of those that contain a lot is increasing. Linoleic acid is easily desaturated in vivo into arachidonic acid, and the resulting leukotriene causes allergy. As society becomes richer, allergies tend to increase due to a decrease in the body's possession of parasites and an increase in fat intake, but no effective antiallergic drugs have been found. Development is an important issue.
【0007】一方、生体のヒアルロン酸含有量を維持
し、高める必要性については、皮膚だけの問題にとどま
らない。大動脈や関節腔液などにおいても、ヒアルロン
酸による保水構造は重要な働きをしている。 老化が人
体のヒアルロン酸含有量の低下という面を伴なう以上、
高齢化社会に向けて、皮膚や血管などの、ヒアルロン酸
により保持される水分含量ひいては柔軟性を維持する必
要性は、ますます高まると予想される。 現状では、化
粧品用保湿剤として外用されるヒアルロン酸にのみ関心
が向けられ、人体内のヒアルロン酸含量、ひいては水分
含量を維持しようとする試みは皆無に等しく、重要な課
題として残されている。On the other hand, the necessity of maintaining and increasing the hyaluronic acid content of a living body is not limited to the problem of skin alone. In the aorta and joint cavity fluid, the water retention structure by hyaluronic acid plays an important role. As aging is accompanied by a decrease in the hyaluronic acid content of the human body,
For an aging society, the need to maintain the moisture content, and thus the flexibility, retained by hyaluronic acid, such as skin and blood vessels, is expected to increase more and more. At present, attention is focused only on hyaluronic acid used externally as a humectant for cosmetics, and there are almost no attempts to maintain the hyaluronic acid content and, consequently, the moisture content in the human body.
【0008】この上記課題の解決は、医薬品の投与によ
っても行なわれるが、食品や化粧品のように日常的に摂
取されたり用いられているものにより講じられることが
より望ましい。 しかし、現在まで、抗炎症、抗アレル
ギー活性、抗ヒアルロニダーゼ活性を持った有望な食品
素材および化粧品原料が得られておらず、このような素
材、原料の提供が課題として残されている。[0008] The above-mentioned problem can be solved by administration of a drug, but it is more preferable that the problem is solved by a substance which is taken or used daily, such as food or cosmetics. However, up to now, promising food materials and cosmetic raw materials having anti-inflammatory, anti-allergic and anti-hyaluronidase activities have not been obtained, and provision of such raw materials and raw materials remains as an issue.
【0009】[0009]
【課題を解決するための手段】本発明者は、上記課題を
解決すべく、アラキドン酸よりPGの合成に至る過程の
初発酵素であるシクロオキシゲナーゼおよびヒアルロン
酸の加水分解酵素であるヒアルロニダーゼの両酵素を阻
害し、かつ抗ヒスタミン活性も有する天然物を見いだす
べく鋭意探索を行った。 ここで、ヒアルロニダーゼ阻
害を目標としたのは、本酵素の阻害が、人体中でのヒア
ルロン酸レベルの維持のみならず、抗炎症や抗アレルギ
ー活性とも強く相関するからである。 本酵素は、炎症
時には活性化され、結合組織のマトリックスを破壊し、
炎症系の細胞および血管の透過性を高める役割りを演じ
ていると考えられるので、本酵素の阻害が抗炎症につな
がるとされる。 また、ヒアルロニダーゼが、肥満細胞
中にあって、IgE−抗原複合体がレセプターに結合す
ることに始まりヒスタミン顆粒の放出(脱顆粒)にまで
至る一連の過程に含まれる可能性が高い。 脱顆粒のよ
うな大きな形態変化は、ヒアルロン酸による保水構造の
一時的破壊なくしては起こり得ないからである。 事
実、抗アレルギー剤の中にはヒアルロニダーゼ阻害活性
を合わせ持つものが多い。Means for Solving the Problems In order to solve the above-mentioned problems, the present inventors have proposed the use of both enzymes, cyclooxygenase, which is the first enzyme in the process from arachidonic acid to PG synthesis, and hyaluronidase, which is a hydrolase of hyaluronic acid. Intensive search was conducted to find a natural product that inhibits and also has antihistamine activity. Here, the reason why the inhibition of hyaluronidase was aimed at is that inhibition of this enzyme strongly correlates with not only maintenance of hyaluronic acid levels in the human body but also anti-inflammatory and anti-allergic activities. This enzyme is activated during inflammation, destroying the matrix of connective tissue,
It is thought that this enzyme plays a role in increasing the permeability of cells and blood vessels of the inflammatory system, so that inhibition of this enzyme is considered to lead to anti-inflammatory. Hyaluronidase is also likely to be involved in a series of processes in mast cells, starting from binding of the IgE-antigen complex to the receptor to release of histamine granules (degranulation). Large morphological changes, such as degranulation, cannot occur without the temporary disruption of the water retention structure by hyaluronic acid. In fact, many antiallergic agents have a hyaluronidase inhibitory activity.
【0010】上記した性質を有する天然物の探索の結
果、甜茶水系溶剤抽出物中に上記の3つの活性を十分に
合わせ持つ物質を発見し、本発明を完成するに至った。As a result of searching for a natural product having the above-mentioned properties, a substance having the above three activities in the extract was found in the tea extract-based solvent extract, and the present invention was completed.
【0011】すなわち本発明の第1の目的は、甜茶抽出
物を有効成分とする、抗炎症剤、抗アレルギー剤および
ヒアルロン酸の分解阻止剤から選ばれる医薬を提供する
ことにある。また、本発明の他の目的は、前記医薬を含
有する食品および化粧品を提供することにある。[0011] That is, a first object of the present invention is to provide a medicament selected from an anti-inflammatory agent, an anti-allergic agent and a hyaluronic acid decomposition inhibitor, which comprises a tea extract as an active ingredient. Another object of the present invention is to provide foods and cosmetics containing the medicine.
【0012】本発明で用いられる甜茶抽出物は、例えば
甜茶を水系溶媒で抽出することにより得られる。 原料
である甜茶(バラ科の多年生潅木、Rubus suavissims
S.Lee)は、中国で古来より甘い茶として用いられてい
る。 この甜茶は、その葉または茎、特に葉を天日で乾
燥したものを原料とし、抽出に付すことができる。な
お、この甜茶は、日本で甘茶として飲用されているユキ
ノシタ科の甘茶[Hydrangea macrophylla Seringe var.
thunbergii Makino(Saxifragaceae:ユキノシタ
科)]とは、全く異なる植物である。The tea tea extract used in the present invention can be obtained, for example, by extracting tea tea with an aqueous solvent. The raw material of tea (Rubaceae perennial shrub, Rubus suavissims
S.Lee) has been used as sweet tea in China since ancient times. This tea can be subjected to extraction using leaves or stems, particularly leaves obtained by drying the leaves in the sun, as raw materials. In addition, this tea is a sweet tea of the family Saxifragaceae [ Hydrangea macrophylla Seringe var.
thunbergii Makino ( Saxifragaceae : Saxifragaceae)] is a completely different plant.
【0013】抽出に用いる水系溶剤は、水単独もしくは
水とメタノール、エタノール等低級アルコール、アセト
ン等の1種または2種の極性溶媒との任意の混合液のい
ずれでもよい。 しかし、極性溶媒だけでは本発明の有
効成分を効率よく抽出できないので、必ず水との混合液
とし、かつ、その混合率は溶媒が90%以下であること
が望ましい。 これらの溶剤のうちでは、抽出物が最終
的に食品等に配合されることを考慮すると、安全性の点
で、水、エタノール、またはこれらの混合物を用いるの
が好ましい。The aqueous solvent used for the extraction may be water alone or any mixture of water and one or two polar solvents such as lower alcohols such as methanol and ethanol, and acetone. However, since the active ingredient of the present invention cannot be efficiently extracted with only a polar solvent, it is desirable to always use a mixed solution with water and the mixing ratio of the solvent is 90% or less. Among these solvents, in view of the fact that the extract is finally incorporated into foods and the like, it is preferable to use water, ethanol, or a mixture thereof from the viewpoint of safety.
【0014】抽出に際しての甜茶と溶剤との比率も特に
限定されるものではないが、甜茶1に対して溶剤2−1
000重量倍、特に抽出操作、効率の点で5−100重
量倍が好ましい。抽出温度は室温−常圧下での溶剤の沸
点の範囲とするのが便利であり、抽出時間は10分から
24時間の範囲とするのが好ましい。The ratio of bean tea to the solvent at the time of extraction is not particularly limited either.
000 times by weight, especially 5-100 times by weight in terms of extraction operation and efficiency. The extraction temperature is conveniently in the range of room temperature to the boiling point of the solvent under normal pressure, and the extraction time is preferably in the range of 10 minutes to 24 hours.
【0015】このようにして得られた甜茶水系溶剤抽出
物そのままのもの、これを濃縮したもの、溶出物から溶
剤を除去した乾燥物等、いかなる状態のものでも使用す
ることが出来るが、保存性、有機溶媒の安全性の点で乾
燥物の状態にするのが好ましい。[0015] Any of the thus obtained bean tea-based solvent extract as it is, a concentrate thereof, and a dried product obtained by removing the solvent from the eluate can be used. It is preferable that the organic solvent is in a dry state in terms of safety.
【0016】本発明の医薬は、甜茶抽出物をそのまま若
しくはこれを公知の医薬用担体と共に製剤化することに
より調製される。本発明の医薬は、錠剤、顆粒剤、粉
剤、シロップ剤等の経口剤;坐剤、外用剤等の非経口剤
のほか、飴、トローチ、ガム、ヨーグルト、アイスクリ
ーム、プディング、ゼリー、水ようかん、コーヒー飲
料、ジュース、炭酸飲料、清涼飲料水、牛乳、乳清飲料
および乳酸菌飲料等の食品に添加する剤形のもの、化粧
水、化粧クリーム、乳液、ファンデーション、口紅、整
髪料、ヘアトニック、育毛料等を始め、歯磨き、洗口
液、シャンプー、リンス、入浴剤等の化粧品に配合する
剤形のものとすることができる。The medicament of the present invention is prepared by preparing a tea extract as it is or with a known pharmaceutical carrier. The medicament of the present invention includes oral preparations such as tablets, granules, powders and syrups; parenteral preparations such as suppositories and external preparations; candy, troches, gums, yogurt, ice cream, puddings, jellies, mizuyokan , Coffee beverages, juices, carbonated beverages, soft drinks, milk, whey beverages, lactic acid bacteria beverages and other dosage forms, lotions, cosmetic creams, emulsions, foundations, lipsticks, hair styling, hair tonics, It can be in the form of a formulation to be incorporated into cosmetics such as hair restorations, toothpastes, mouthwashes, shampoos, rinses, bath additives and the like.
【0017】本発明の医薬の調製に用いることのできる
医薬用担体としては、特に制限はなく、通常用いられて
いるものを使用することができるが、その例としては、
デンプン、乳糖、白糖、マンニット、カルボキシメチル
セルロース、コーンスターチ、無機塩等の固形担体;蒸
留水、生理食塩水、ブドウ糖水溶液、エタノール等のア
ルコール、プロピレングリコール、ポリエチレングリコ
ール等の液体担体;各種の動植物油、白色ワセリン、パ
ラフィン、ロウ類等の油性担体等が挙げられる。The pharmaceutical carrier that can be used in the preparation of the medicament of the present invention is not particularly limited, and those usually used can be used.
Solid carriers such as starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch and inorganic salts; distilled water, physiological saline, aqueous glucose solutions, alcohols such as ethanol, liquid carriers such as propylene glycol and polyethylene glycol; various animal and vegetable oils And oily carriers such as white petrolatum, paraffin and waxes.
【0018】また、本発明の医薬を用いて、上記の食品
や化粧品、歯磨き、シャンプー等を製造するには、その
製品の種類に応じて通常用いられる適宜な成分を配合す
ることができる。 例えば、食品を調製する場合には、
ブドウ糖、果糖、ショ糖、マルトース、ソルビトール、
ステビオサイド、ルブソサイド、コーンシロップ、乳
糖、クエン酸、酒石酸、リンゴ酸、コハク酸、乳酸、L
−アスコルビン酸、dl−α−トコフェロール、エリソ
ルビン酸ナトリウム、グリセリン、プロピレングリコー
ル、グリセリン脂肪酸エステル、ポリグリセリン脂肪酸
エステル、ショ糖脂肪酸エステル、ソルビタン脂肪酸エ
ステル、プロピレングリコール脂肪酸エステル、アラビ
アガム、カラギーナン、カゼイン、ゼラチン、ペクチ
ン、寒天、ビタミンB類、ニコチン酸アミド、パントテ
ン酸カルシウム、アミノ酸類、カルシウム塩類、色素、
香料、保存剤等、通常の食品原料として使用されている
ものを適宜配合して製造することが出来る。In order to produce the above-mentioned foods, cosmetics, toothpastes, shampoos and the like using the medicament of the present invention, appropriate components usually used depending on the type of the product can be blended. For example, when preparing food,
Glucose, fructose, sucrose, maltose, sorbitol,
Stevioside, rubusoside, corn syrup, lactose, citric acid, tartaric acid, malic acid, succinic acid, lactic acid, L
-Ascorbic acid, dl-α-tocopherol, sodium erysorbate, glycerin, propylene glycol, glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, gum arabic, carrageenan, casein, gelatin , Pectin, agar, vitamin B, nicotinamide, calcium pantothenate, amino acids, calcium salts, pigment,
It can be produced by appropriately blending those used as ordinary food ingredients such as flavors and preservatives.
【0019】更に、化粧品を調製する場合には、植物油
等の油脂類、ラノリンやミツロウ等のロウ類、炭化水素
類、脂肪酸、高級アルコール類、エステル類、種々の界
面活性剤、色素、香料、ビタミン類、植物・動物抽出成
分、紫外線吸収剤、抗酸化剤、防腐・殺菌剤等、通常の
化粧品原料として使用されているものを適宜配合して製
造することができる。Further, when preparing cosmetics, oils and fats such as vegetable oils, waxes such as lanolin and beeswax, hydrocarbons, fatty acids, higher alcohols, esters, various surfactants, pigments, fragrances, It can be produced by appropriately blending those commonly used as raw materials for cosmetics, such as vitamins, plant / animal extract components, ultraviolet absorbers, antioxidants, preservatives and bactericides.
【0020】本発明の甜茶抽出物を用いて化粧品等を調
製する場合には、他の抗炎症・抗アレルギー性化粧品原
料、例えば、甘草抽出成分(特にグリチルリチン酸)、
塩酸ジフェンヒドラミン、アズレン、dl−α−トコフ
ェロールおよびその誘導体、ビタミンB2及びB6などと
用いることにより、その効果を高めることができる。甜
茶抽出物はヒアルロン酸分解酵素であるヒアルロニダー
ゼを強く阻害するのでヒアルロン酸と共に用いることに
より、その保湿効果を一層高めることができる。 甜茶
抽出物単独でも、皮膚中のヒアルロン酸の分解を阻止す
ることにより間接的に保湿・美肌効果を持つが、他の保
湿・美肌性化粧品成分、例えば、エラスチン、コラーゲ
ン、レシチン、スクワレン、プラセンターリキッド(胎
盤抽出液)、グリセリン類、グリコール類、発酵代謝産
物、乳酸菌培養液、ビタミンAおよびC、コンドロイチ
ン硫酸ナトリウム、2−ピロリドン−5−カルボン酸ナ
トリウム(PCA−Na)、バクモンドウ粘液多糖類等
の植物多糖類などと共に用いて、より一層効果を高める
ことが望ましい。In the case of preparing cosmetics and the like using the tea tea extract of the present invention, other anti-inflammatory and anti-allergic cosmetic raw materials, for example, licorice extract component (particularly glycyrrhizic acid),
Diphenhydramine hydrochloride, azulene, dl-alpha-tocopherol and its derivatives, the use of a vitamin B 2 and B 6, it is possible to enhance the effect. Since the bean tea extract strongly inhibits hyaluronidase, a hyaluronic acid-degrading enzyme, its use in combination with hyaluronic acid can further enhance its moisturizing effect. The tea tea extract alone has a moisturizing / beautifying skin effect indirectly by inhibiting the decomposition of hyaluronic acid in the skin, but other moisturizing / beautifying cosmetic ingredients such as elastin, collagen, lecithin, squalene and placenta. Liquid (placental extract), glycerin, glycols, fermentation metabolite, lactic acid bacteria culture, vitamin A and C, sodium chondroitin sulfate, sodium 2-pyrrolidone-5-carboxylate (PCA-Na), Bacmondou mucus polysaccharide, etc. It is desirable to further enhance the effect when used together with a plant polysaccharide or the like.
【0021】甜茶は古来より中国では甘い茶として用い
られており、本発明で使用するその抽出物は安全性の点
での問題はない。 しかし、本発明の医薬における甜茶
抽出物の配合量は、効果および添加した際の香り、色調
の点で、乾燥重量換算で、0.01−5.0%の濃度範囲
とすることが望ましい。Sweet tea has been used as sweet tea in China since ancient times, and the extract used in the present invention has no problem in terms of safety. However, it is desirable that the amount of the extract of bean tea in the medicament of the present invention be in the concentration range of 0.01 to 5.0% in terms of dry weight in terms of the effect, the scent when added, and the color tone.
【0022】[0022]
【作用および発明の効果】本発明医薬の有効成分である
甜茶抽出物のシクロオキシゲナーゼ阻害活性、すなわち
PG合成の阻害による抗炎症活性はアスピリンのそれの
約1/5であり、抗ヒスタミン活性は抗アレルギー薬イ
ンタールの活性成分であるDSCGのそれに匹敵した。
従って、本発明の医薬は抗炎症作用および抗アレルギ
ー作用を有する医薬として有用なものである。 また、
甜茶抽出物を含む食品を日常的に摂取することにより、
風邪に伴なう炎症やのどのはれ、花粉症、せきなどを予
防・改善することができる。 同様に、甜茶抽出物を含む
化粧品の使用により、皮膚のかゆみなどを改善すること
が可能である。The cyclooxygenase inhibitory activity of the extract of bean tea, which is the active ingredient of the medicament of the present invention, ie, the anti-inflammatory activity by inhibiting PG synthesis is about 1/5 of that of aspirin, and the antihistamine activity is anti-allergic. It was comparable to that of DSCG, the active ingredient of the drug Intal.
Therefore, the medicament of the present invention is useful as a medicament having an anti-inflammatory action and an anti-allergic action. Also,
By ingesting foods containing bean tea extract on a daily basis,
It can prevent and improve inflammation, sore throat, hay fever, cough, etc. associated with a cold. Similarly, it is possible to improve skin itchiness and the like by using a cosmetic containing the tea extract.
【0023】本発明による甜茶抽出物は強力なヒアルロ
ン酸分解阻止剤として皮膚や動脈壁、関節腔などに含ま
れるヒアルロン酸含量の低下を抑制する。このことによ
り、間接的作用ではあるが、皮膚の保湿性および柔軟性
を高め、加齢に伴なう動脈硬化を予防し、関節炎の改善
などに寄与する。The bean tea extract according to the present invention is a powerful inhibitor of the degradation of hyaluronic acid and suppresses a decrease in the content of hyaluronic acid contained in skin, arterial walls, joint cavities and the like. Although this is an indirect effect, it enhances the moisturizing property and flexibility of the skin, prevents arteriosclerosis associated with aging, and contributes to improvement of arthritis.
【0024】甜茶抽出物は、安全性の確立された植物抽
出物であり、かつ、抗炎症剤、抗アレルギー剤としての
作用の他にヒアルロン酸分解阻止剤としての種々の効果
を合わせ持っており、その多機能性は他に例を見ないも
のである。The bean tea extract is a plant extract whose safety has been established, and has various effects as a hyaluronic acid degradation inhibitor in addition to its action as an anti-inflammatory and anti-allergic agent. , Its versatility is unparalleled.
【0025】[0025]
【実施例】次に甜茶抽出物の製造法、シクロオキシゲナ
ーゼ阻害試験、ヒアルロニダーゼ阻害試験、ヒスタミン
遊離抑制試験および抗炎症剤、抗アレルギー剤並びにヒ
アルロン酸の分解阻止剤の製造に関する実施例を挙げ、
本発明を更に詳しく説明する。 実 施 例 1 甜茶抽出物の製造:甜茶 100gを3000mlの三
角フラスコにいれ、熱水 1000mlを加え、沸騰水
浴中で3時間抽出を行った。 これを濾過し、得た濾液
を凍結乾燥し、抽出物 32.3gを得た(甜茶抽出物
1)。Examples Next, examples relating to a method for producing a tea tea extract, a cyclooxygenase inhibition test, a hyaluronidase inhibition test, a histamine release inhibition test, and production of an anti-inflammatory agent, an anti-allergic agent and a hyaluronic acid degradation inhibitor will be described.
The present invention will be described in more detail. Example 1 Production of a tea extract: 100 g of tea was placed in a 3000 ml Erlenmeyer flask, added with 1000 ml of hot water, and extracted in a boiling water bath for 3 hours. This was filtered, and the obtained filtrate was freeze-dried to obtain 32.3 g of an extract (Tengcha extract 1).
【0026】実 施 例 2 甜茶抽出物の製造:甜茶 100gを3000mlの三
角フラスコにいれ、50容量%のエタノール1000m
lを加え、室温下で、1時間ごとに軽く撹拌し、24時
間抽出を行った。 これを濾過し、得た濾液を減圧下濃
縮してエタノールを除去後、水を加えて凍結乾燥し、抽
出物 31.1gを得た(甜茶抽出物2)。Example 2 Production of a tea extract: 100 g of tea is placed in a 3000 ml Erlenmeyer flask, and 50% by volume of ethanol 1000 m
l, and the mixture was gently stirred every hour at room temperature and extracted for 24 hours. This was filtered, the obtained filtrate was concentrated under reduced pressure to remove ethanol, water was added, and the mixture was freeze-dried to obtain 31.1 g of an extract (Tengcha extract 2).
【0027】実 施 例 3 シクロオキシゲナーゼ阻害活性の検定:実施例1で得た
抽出物について、下記の方法で、そのシクロオキシゲナ
ーゼ阻害活性を測定した。 その結果を表1に示す。Example 3 Assay of cyclooxygenase inhibitory activity: The extract obtained in Example 1 was measured for its cyclooxygenase inhibitory activity by the following method. Table 1 shows the results.
【0028】( 測 定 法 )羊精嚢腺ミクロゾーム(フ
ナコシ薬品、メーカーコードA3)のシクロオキシゲナ
ーゼ活性に対する阻害効果を酸素吸収法により測定し
た。すなわち、酸素電極を備えた4ml容の反応槽に、
10mMのL−トリプトファンを含む0.2Mトリス塩
酸緩衝液(pH8.0)3.835ml、40μMヘモグ
ロビン液25μl、被験試料液100μlおよびミクロ
ゾーム0.6mgを含む上記緩衝液30μlを加え、5
分間プレインキュベートした後、エタノールに溶かした
10mMアラキドン酸液10μlの添加により反応を開
始させた。反応温度は30℃である。 被験試料液の代
わりに精製水を加えた対照の初発酵素吸収速度をC、被
験試料添加時のそれをSとして、以下の計算式により阻
害率I(%)を求めた。 I(%)=100×(C−S)/C 甜茶および羅漢果抽出物とも、阻害活性の用量依存曲線
は直線性を示さず、I=50%付近に変曲点を持つS字
型となった。(Measurement Method) The inhibitory effect of the microsomal of sheep seminal vesicle gland (Funakoshi Pharmaceutical Co., manufacturer code A3) on the cyclooxygenase activity was measured by an oxygen absorption method. That is, in a 4 ml reactor equipped with an oxygen electrode,
3.835 ml of 0.2 M Tris-HCl buffer (pH 8.0) containing 10 mM L-tryptophan, 25 μl of 40 μM hemoglobin solution, 30 μl of the above buffer containing 100 μl of test sample solution and 0.6 mg of microsome were added, and 5
After preincubation for 10 minutes, the reaction was started by adding 10 μl of a 10 mM arachidonic acid solution in ethanol. The reaction temperature is 30 ° C. The inhibition rate I (%) was determined by the following formula, where C was the initial enzyme absorption rate of the control to which purified water was added instead of the test sample solution, and S was that at the time of addition of the test sample. I (%) = 100 × (C−S) / C In both the tea tea and the extract of Arhat fruit, the dose-dependent curve of the inhibitory activity did not show linearity, and became S-shaped with an inflection point around I = 50%. Was.
【0029】[0029]
【表1】 [Table 1]
【0030】実 施 例 4 ヒアルロニダーゼ阻害活性の検定:実施例1で得た抽出
物について、下記の方法で、そのヒアルロニダーゼ阻害
活性を測定した。 その結果を表2に示す。Example 4 Assay of hyaluronidase inhibitory activity: The extract obtained in Example 1 was measured for its hyaluronidase inhibitory activity by the following method. Table 2 shows the results.
【0031】( 測 定 法 )牛睾丸由来のヒアルロニダ
ーゼ(Sigma,TypeIV)を用いて、コンパウ
ンド 48/80による、不活性型酵素の活性化段階の
阻害作用を中心に測定した。酵素活性は、ヒアルロン酸
の加水分解により生成するN−アセチルヘキソサミンを
還元末端とする四糖の還元力の増加をA585で比色定量
することにより、測定した(前田 有美恵ら:食衛誌、
31巻、233−237頁、1990)。すなわち、適量の
被験試料を0.1M酢酸緩衝液(pH4.0)100μl
に溶かして試験管にとり、同緩衝液 50μlに溶かし
た酵素 0.10mg(100NF units)を加
え、37℃−20分間インキュベートした後、同緩衝液
に100μlに溶かしたコンパウンド 48/80(5
0μg)を加え、更に37℃−20分間インキュベート
する。最後に、同緩衝液250μlに溶かしたヒアルロ
ン酸ナトリウム塩(200μg、微生物由来)を加え
て、37℃− 40分間インキュベートした後、0.4N
NaOH 100μlを加えて氷冷後、ホウ酸緩衝液
(pH9.1)100μlを加えて3分間煮沸する。氷
冷後、p−ジメチルアミノベンズアルデヒド試液 3m
lを加えて、37℃−20分間インキュベート後、A
585を測定した。対照には試料溶液の代わりに上記酢酸
緩衝液を用いた。また、それぞれのブランクとして、酵
素溶液の代わりに上記酢酸緩衝液を用いた。阻害活性は
次の式から求められる阻害率で表した。 A: 対照溶液のA585 B: 対照溶液のブランクのA585 C: 試料溶液のA585 D: 試料溶液のブランクのA585 (Measurement Method) Using hyaluronidase (Sigma, Type IV) derived from bovine testes, the inhibitory effect of compound 48/80 on the activation stage of the inactive enzyme was measured mainly. Enzyme activity, an increase in the reducing power of tetrasaccharide to the N- acetylhexosamine produced by hydrolysis of hyaluronic acid and the reducing end by colorimetry at A 585, was determined (Yumi Maeda Megumira: ShokuMamorushi ,
31, 233-237, 1990). That is, an appropriate amount of a test sample was added to 100 μl of a 0.1 M acetate buffer (pH 4.0).
Was added to the test tube, 0.10 mg (100 NF units) of the enzyme dissolved in 50 μl of the same buffer was added, and the mixture was incubated at 37 ° C. for 20 minutes. Then, the compound 48/80 (5
0 μg) and further incubate at 37 ° C. for 20 minutes. Finally, sodium hyaluronate (200 µg, derived from a microorganism) dissolved in 250 µl of the same buffer was added, and the mixture was incubated at 37 ° C for 40 minutes.
After adding 100 μl of NaOH and cooling with ice, add 100 μl of borate buffer (pH 9.1) and boil for 3 minutes. After cooling on ice, p-dimethylaminobenzaldehyde TS 3m
After incubating at 37 ° C. for 20 minutes,
585 was measured. As a control, the above acetate buffer was used instead of the sample solution. Further, as each blank, the above acetate buffer was used instead of the enzyme solution. The inhibitory activity was represented by the inhibition rate determined from the following equation. A: A 585 B control solution: A 585 of control solution blanks C: A 585 D of the sample solution: the blank of the sample solution A 585
【0032】[0032]
【表2】 * ジソジウムクロモグリケート(商品名 インタール)[Table 2] * Disodium chromoglycate (product name: Intal)
【0033】実 施 例 5 肥満細胞からのヒスタミン遊離抑制試験:実施例1で得
た抽出物について、下記の方法で、そのヒスタミン遊離
抑制活性を測定した(平井 裕子ら:生薬学雑誌、37
巻、374−380、1983)。その結果を表3に示す。Example 5 Test for Inhibiting Histamine Release from Mast Cells: The extract obtained in Example 1 was assayed for its histamine release inhibitory activity by the following method (Yuko Hirai et al .: Pharmaceutical Pharmaceutical Magazine, 37).
374-380, 1983). Table 3 shows the results.
【0034】( 測 定 法 )脱血致死させたウィスター
系ラットの腹腔内にタイロード(Tyrode)液を注
入して採取した腹腔細胞から、牛血清アルブミン(BS
A)−生理食塩水(比重1.068)を用いる重層遠心
法により肥満細胞を単離した。得られた細胞は2×10
6個/mlとなるように0.1%BSA含有タイロード液
に懸濁し、細胞浮遊液を調製した。試料溶液 10μl
に細胞浮遊液10μlを加えて37℃−10分間放置し
た後、脱顆粒誘発剤としてコンパウンド 48/80
(5μg/ml)20μlを加えて37℃−10分間反
応させた。 その後、いったん氷冷し、遠心分離(15
0×g、5分)した上清中に遊離されたヒスタミン量を
蛍光検出器付き高速液体クロマトグラフィーにより測定
した。ヒスタミン遊離抑制活性は次式により算出した。 ヒスタミン遊離抑制率(%)=100×[1−(SR−
C)/(R−C)] C: 対照の細胞から遊離されるヒスタミン量 R: 誘発剤を加えたときに細胞から遊離されるヒスタ
ミン量 SR:試料を共存させて誘発剤を加えたときに細胞から
遊離されるヒスタミン量(Measurement method) Bovine serum albumin (BS) was collected from peritoneal cells collected by injecting Tyrode solution into the abdominal cavity of Wistar rats that had been bled to death.
A)-Mast cells were isolated by a double-layer centrifugation method using physiological saline (specific gravity: 1.068). The cells obtained were 2 × 10
The cells were suspended in Tyrode's solution containing 0.1% BSA at a concentration of 6 cells / ml to prepare a cell suspension. Sample solution 10μl
After adding 10 μl of the cell suspension to the mixture and allowing it to stand at 37 ° C. for 10 minutes, Compound 48/80 was used as a degranulation-inducing agent.
20 μl (5 μg / ml) was added and reacted at 37 ° C. for 10 minutes. Thereafter, the mixture was cooled on ice once and centrifuged (15
(0 × g, 5 minutes), the amount of histamine released in the supernatant was measured by high performance liquid chromatography with a fluorescence detector. The histamine release inhibitory activity was calculated by the following equation. Histamine release inhibition rate (%) = 100 × [1- (SR−
C) / (RC)] C: The amount of histamine released from control cells R: The amount of histamine released from cells when an inducer is added SR: When the inducer is added in the presence of a sample Histamine release from cells
【0035】[0035]
【表3】 * ジソジウムクロモグリケート(商品名 インタール)[Table 3] * Disodium chromoglycate (product name: Intal)
【0036】実 施 例 6 錠 剤:150gの甜茶抽出物1を同量の乳糖及びス
テアリン酸マグネシウム5gと混合し、この混合物を単
発式打錠機にて打錠し、直径10mm、重量300mg
の錠剤を製造した。Example 6 Tablets: 150 g of bean tea extract 1 was mixed with the same amounts of lactose and magnesium stearate (5 g), and the mixture was tableted with a single-shot tableting machine to a diameter of 10 mm and a weight of 300 mg.
Tablets were produced.
【0037】実 施 例 7 顆 粒 剤:実施例6で得た錠剤を粉砕、整粒し、篩別し
て20−50メッシュの顆粒剤を得た。Example 7 Condyle Granules: The tablets obtained in Example 6 were pulverized, sized, and sieved to obtain 20-50 mesh granules.
【0038】実 施 例 8 飴 : ( 組 成 ) ( 重 量 部 ) 粉末ソルビトール 99.7 香 料 0.2 甜 茶 抽 出 物 0.05 ソルビトールシード 0.05 全 量 100Example 8 Candy: (composition) (weight part) Powdered sorbitol 99.7 Perfume 0.2 Teng tea extract 0.05 Sorbitol seed 0.05 Total amount 100
【0039】実 施 例 9 キャンデー: ( 組 成 ) ( 重 量 部 ) 砂 糖 47.0 水 飴 49.76 香 料 1.0 水 2.0 甜茶抽出物 0.24 全 量 100Example 9 Candy: (composition) (weight) sugar 47.0 water syrup 49.76 fragrance 1.0 water 2.0 sweet tea extract 0.24 total amount 100
【0040】実 施 例 10 トローチ: ( 組 成 ) ( 重 量 部 ) アラビアゴム 6 ブドウ糖 73 甜茶抽出物 0.05 リン酸第二カリウム 0.2 リン酸第一カリウム 0.1 乳 糖 17 香 料 0.1 ステアリン酸マグネシウム 残 量 全 量 100Example 10 Lozenges (composition) (weight) Gum arabic 6 Glucose 73 Tengcha extract 0.05 Potassium potassium phosphate 0.2 Potassium potassium phosphate 0.1 Lactose 17 Fragrance 0.1 Magnesium stearate Remaining amount 100
【0041】実 施 例 11 ガ ム: ( 組 成 ) ( 重 量 部 ) ガムベース 20 炭酸カルシウム 2 ステビオサイド 0.1 甜茶抽出物 0.05 乳 糖 76.85 香 料 1 全 量 100EXAMPLE 11 GAM: (Composition) (weight part) Gum base 20 Calcium carbonate 2 Stevioside 0.1 Teng tea extract 0.05 Lactose 76.85 Flavor 1 Total amount 100
【0042】実 施 例 12 チューインガム: ( 組 成 ) ( 重 量 部 ) ガムベース 20.0 砂 糖 75.62 香 料 1.0 クエン酸 1.0 水 2.0 甜茶抽出物 0.38 全 量 100Example 12 Chewing Gum: (Composition) (Weight) Gum Base 20.0 Sugar 75.62 Flavor 1.0 Citric Acid 1.0 Water 2.0 Tian Tea Extract 0.38 Total 100
【0043】実 施 例 13 キャラメル: ( 組 成 ) ( 重 量 部 ) グラニュー糖 32.0 水 飴 20.0 粉 乳 40.0 硬 化 油 4.0 食 塩 0.6 香 料 0.02 水 3.22 甜茶抽出物 0.16 全 量 100Example 13 Caramel: (composition) (weight part) Granulated sugar 32.0 Water candy 20.0 Powdered milk 40.0 Hardened oil 4.0 Food salt 0.6 Flavor 0.02 Water 3.22 Tengcha extract 0.16 Total amount 100
【0044】実 施 例 14 コーヒーゼリー: ( 組 成 ) ( 重 量 部 ) グラニュー糖 15.0 ゼ ラ チ ン 1.0 コーヒーエキス 5.0 水 78.93 甜茶抽出物 0.07 全 量 100Example 14 Coffee Jelly: (Composition) (weight part) Granulated sugar 15.0 Gelatin 1.0 Coffee extract 5.0 Water 78.93 Teng tea extract 0.07 Total amount 100
【0045】実 施 例 15 アイスクリーム: ( 組 成 ) ( 重 量 部 ) 生クリーム(45%脂肪) 33.8 脱脂粉乳 11.0 グラニュー糖 14.8 加糖卵黄 0.3 バニラエッセンス 0.1 水 39.93 甜茶抽出物 0.07 全 量 100Example 15 Ice cream: (composition) (weight) fresh cream (45% fat) 33.8 skim milk powder 11.0 granulated sugar 14.8 sweetened egg yolk 0.3 vanilla extract 0.1 water 39.93 Tengcha extract 0.07 Total amount 100
【0046】実 施 例 16 カスタードプディング: ( 組 成 ) ( 重 量 部 ) 牛 乳 47.51 全 卵 31.9 上 白 糖 17.1 水 3.4 甜茶抽出物 0.09 全 量 100Example 16 Custard Pudding: (Composition) (Weight) Milk 47.51 Whole Egg 31.9 Upper Sugar 17.1 Water 3.4 Teng Tea Extract 0.09 Total 100
【0047】実 施 例 17 水ようかん: ( 組 成 ) ( 重 量 部 ) 赤生あん 24.8 粉末寒天 0.3 食 塩 0.1 上 白 糖 24.9 甜茶抽出物 0.1 水 49.8 全 量 100Example 17 Mizuyokan: (Composition) (Weight) Akasei bean 24.8 Powder agar 0.3 Dietary salt 0.1 Kamikasu 24.9 Teng tea extract 0.1 Water 49. 8 Total amount 100
【0048】実 施 例 18 ジュース: ( 組 成 ) ( 重 量 部 ) 冷凍濃縮温州みかん果汁 5 果糖ブドウ糖液糖 11 クエン酸 0.2 L−アスコルビン酸 0.02 甜茶抽出物 0.05 香 料 0.2 色 素 0.1 水 残 量 全 量 100Example 18 Juice: (composition) (weight part) Frozen-concentrated unshu mandarin orange juice 5 fructose-glucose liquid sugar 11 citric acid 0.2 L-ascorbic acid 0.02 sweet tea extract 0.05 flavoring 0 .2 Color element 0.1 Total amount of water remaining 100
【0049】実 施 例 19 炭酸飲料: ( 組 成 ) ( 重 量 部 ) グラニュー糖 8.0 濃縮レモン果汁 1.0 L−アスコルビン酸 0.10 クエン酸 0.06 クエン酸ナトリウム 0.05 着 色 料 0.05 香 料 0.15 炭 酸 水 90.55 甜茶抽出物 0.04 全 量 100Example 19 Carbonated Drink: (Composition) (Weight) Granulated Sugar 8.0 Concentrated Lemon Juice 1.0 L-Ascorbic Acid 0.10 Citric Acid 0.06 Sodium Citrate 0.05 Coloring Ingredients 0.05 Perfume 0.15 Carbonated water 90.55 Tengcha extract 0.04 Total amount 100
【0050】実 施 例 20 乳酸菌飲料: ( 組 成 ) ( 重 量 部 ) 乳固形分21%発酵乳 14.76 果糖ブドウ糖液糖 13.31 ペ ク チ ン 0.5 ク エ ン 酸 0.08 香 料 0.15 水 71.14 甜茶抽出物 0.06 全 量 100EXAMPLE 20 Lactic Acid Bacteria Beverage: (Composition) (Weight) 21% Milk Solids Fermented Milk 14.76 Fructose Dextrose Liquid Sugar 13.31 Peptin 0.5 Cuenoic Acid 0.08 Flavor 0.15 Water 71.14 Tengcha extract 0.06 Total 100
【0051】実 施 例 21 コーヒー飲料: ( 組 成 ) ( 重 量 部 ) グラニュー糖 8.0 脱 脂 粉 乳 5.0 カ ラ メ ル 0.2 コーヒー抽出物 2.0 香 料 0.1 ポリグリセリン 0.05 脂肪酸エステル 食 塩 0.05 水 84.56 甜茶抽出物 0.04 全 量 100EXAMPLE 21 Coffee Beverage: (Composition) (Weight) Granulated Sugar 8.0 Skim Powdered Powder 5.0 Caramel 0.2 Coffee Extract 2.0 Flavor 0.1 Poly Glycerin 0.05 Fatty acid ester Dietary salt 0.05 Water 84.56 Tea extract 0.04 Total amount 100
【0052】実 施 例 22 歯磨剤: ( 組 成 ) ( 重 量 部 ) 第二リン酸カルシウム 42 グリセリン 18 カラギーナン 0.9 ラウリル硫酸ナトリウム 1.2 サッカリンナトリウム 0.09 パラオキシ安息香酸ブチル 0.005 甜茶抽出物 0.05 香 料 1 水 残 量 全 量 100Example 22 Dentifrice: (Composition) (Weight) Calcium Diphosphate 42 Glycerin 18 Carrageenan 0.9 Sodium Lauryl Sulfate 1.2 Sodium Saccharin 0.09 Butyl Paraoxybenzoate 0.005 Tea Tea Extract 0 .05 Perfume 1 Water balance 100
【0053】実 施 例 23 洗口液: ( 組 成 ) ( 重 量 部 ) ラウリル硫酸ナトリウム 0.8 グリセリン 7 ソルビトール 5 エチルアルコール 15 甜茶抽出物 0.05 1−メントール 0.05 香 料 0.04 サッカリンナトリウム 0.1 水 残 量 全 量 100Example 23 Mouthwash: (composition) (weight part) Sodium lauryl sulfate 0.8 glycerin 7 sorbitol 5 ethyl alcohol 15 Tengcha extract 0.05 1-menthol 0.05 05 Fragrance 0.04 Saccharin sodium 0.1 Water remaining amount Total amount 100
【0054】実 施 例 24 柔軟化粧水(弱酸性): ( 組 成 ) ( 重 量 部 ) グリセリン 5.0 プロピレングリコール 4.0 ヒアルロン酸ナトリウム 0.1 甜茶抽出物 0.05 ポリオキシエチレンソルビタン モノラウリン酸エステル 1.5 (20E.O.) ポリオキシエチレンラウリル 0.5 エーテル(20E.O.) エタノール 10.0 香 料 0.1 染 料 適 量 防 腐 剤 適 量 紫外線吸収剤 適 量 精 製 水 78.75Example 24 Softening lotion (weakly acidic): (Composition) (weight part) Glycerin 5.0 Propylene glycol 4.0 Sodium hyaluronate 0.1 Teng tea extract 0.05 Polyoxyethylene sorbitan monolaurin Acid ester 1.5 (20 EO) Polyoxyethylene lauryl 0.5 ether (20 EO) Ethanol 10.0 Flavor 0.1 Dyeing dye proper amount Preservative proper amount UV absorber proper amount Refining Water 78.75
【0055】実 施 例 25 エモリエントクリーム: ( 組 成 ) ( 重 量 部 ) ミツロウ 2.0 ステアリルアルコール 5.0 ステアリン酸 8.0 スクアラン 10.0 自己乳化型プロピレングリコール 3.0 モノステアレート ポリオキシエチレンセチルエーテル 1.0 (20E.O.) 香 料 0.5 防腐剤 適 量 酸化防止剤 適 量 プロピレングリコール 7.8 グリセリン 4.0 ヒアルロン酸ナトリウム 0.1 甜茶抽出物 0.1 トリエタノールアミン 1.0 精 製 水 57.5Example 25 Emollient Cream: (Composition) (Weight) Beeswax 2.0 Stearyl Alcohol 5.0 Stearic Acid 8.0 Squalane 10.0 Self-Emulsifying Propylene Glycol 3.0 Monostearate Polyoxy Ethylene cetyl ether 1.0 (20EO) Fragrance 0.5 Preservatives Qs Antioxidant Qs Propylene glycol 7.8 Glycerin 4.0 Sodium hyaluronate 0.1 Teng tea extract 0.1 Triethanolamine 1.0 Refined water 57.5
【0056】実 施 例 26 エモリエントローション: ( 組 成 ) ( 重 量 部 ) ステアリン酸 2.0 セタノール 1.5 ワセリン 3.0 ラノリンアルコール 2.0 流動パラフィン 10.0 ポリオキシエチレンモノオレイン酸 2.0 エステル(10E.O.) 香 料 0.5 酸化防止剤 適 量 防 腐 剤 適 量 プロピレングリコール 4.8 グリセリン 3.0 ヒアルロン酸ナトリウム 0.1 甜茶抽出物 0.1 トリエタノールアミン 1.0 精 製 水 70.0Example 26 Emollient lotion: (composition) (weight) stearic acid 2.0 cetanol 1.5 petrolatum 3.0 lanolin alcohol 2.0 liquid paraffin 10.0 polyoxyethylene monooleic acid 2. 0 Ester (10EO) Fragrance 0.5 Antioxidant Appropriate amount Preservative Appropriate amount Propylene glycol 4.8 Glycerin 3.0 Sodium hyaluronate 0.1 Teng tea extract 0.1 Triethanolamine 1.0 Refined water 70.0
【0057】実 施 例 27 乳液状ファンデーション: ( 組 成 ) ( 重 量 部 ) ステアリン酸 2.4 モノステアリン酸プロピレン 2.0 グリコール セトステアリルアルコール 0.2 液状ラノリン 2.0 流動パラフィン 3.0 ミリスチン酸イソプロピル 8.5 パラオキシ安息香酸プロピル 適 量 精 製 水 64.1 カルボキシメチルセルロースナトリウム 0.2 ベントナイト 0.5 プロピレングリコール 3.8 ヒアルロン酸ナトリウム 0.1 甜茶抽出物 0.1 トリエタノールアミン 1.1 パラオキシ安息香酸メチル 適 量 酸化チタン 8.0 タ ル ク 4.0 着色顔料 適 量 香 料 適 量Example 27 Emulsion foundation: (composition) (weight) stearic acid 2.4 propylene monostearate 2.0 glycol setosteryl alcohol 0.2 liquid lanolin 2.0 liquid paraffin 3.0 myristin Isopropyl acid 8.5 8.5 Propyl parahydroxybenzoate qs Refined water 64.1 sodium carboxymethylcellulose 0.2 bentonite 0.5 propylene glycol 3.8 sodium hyaluronate 0.1 bean tea extract 0.1 triethanolamine 1.1 Methyl parahydroxybenzoate qs Titanium oxide 8.0 talc 4.0 color pigment qs perfume qs
【0058】実 施 例 28 育毛ヘアトニック: ( 組 成 ) ( 重 量 部 ) エタノール 70.0 センブリエキス 0.2 ビタミンE 0.2 L−メントール 0.4 グリチルリチン 0.1 甜茶抽出物 0.1 サリチル酸 0.5 グリセリン 0.5 香 料 適 量 精 製 水 28.0Example 28 Hair Restoration Hair Tonic: (Composition) (Weight) Ethanol 70.0 Assembly Extract 0.2 Vitamin E 0.2 L-Menthol 0.4 Glycyrrhizin 0.1 Teng Tea Extract 0.1 Salicylic acid 0.5 Glycerin 0.5 Perfume Appropriate amount Purified water 28.0
【0059】実 施 例 29 シャンプー: ( 組 成 ) ( 重 量 部 ) アルキルエーテル硫酸 16.0 ナトリウム(AES−Na) ラウリン酸ジエタノールアミド 4.0 プロピレングリコール 1.9 甜茶抽出物 0.1 防腐剤、色素、香料 適 量 精 製 水 78.0EXAMPLE 29 Shampoo: (Composition) (Weight) Alkyl ether sulfate 16.0 Sodium (AES-Na) Lauric acid diethanolamide 4.0 Propylene glycol 1.9 Teng tea extract 0.1 Preservative , Pigment, fragrance Appropriate amount Purified water 78.0
【0060】実 施 例 30 リンス: ( 組 成 ) ( 重 量 部 ) 塩化ステアリルジメチル 1.4 ベンジルアンモニウム ステアリルアルコール 0.6 グリセリンモノステアレート 1.5 食 塩 0.1 甜茶抽出物 0.1 精 製 水 96.3 以 上Example 30 Rinse: (composition) (weight part) Stearyl dimethyl chloride 1.4 Benzyl ammonium stearyl alcohol 0.6 Glycerin monostearate 1.5 Food salt 0.1 Teng tea extract 0.1 Purified Water production 96.3 or more
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI A23G 9/00 A23G 9/00 A23L 1/06 A23L 1/06 1/187 1/187 1/30 1/30 B 2/38 2/38 C 2/52 A61K 7/00 K A61K 7/00 W 7/02 P 7/02 7/06 7/06 7/075 7/075 7/08 7/08 7/26 7/26 7/48 7/48 7/50 7/50 9/20 9/20 A61P 17/00 A61P 17/00 37/08 37/08 43/00 113 43/00 113 A23L 2/00 F (58)調査した分野(Int.Cl.7,DB名) A61K 35/78 A23C 9/13 A23G 3/00 A23G 9/00 A23L 1/06 A23L 2/38 A23L 2/52 A61K 7/00 A61K 9/20 BIOSIS(DIALOG) CA(STN) MEDLINE(STN)──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification code FI A23G 9/00 A23G 9/00 A23L 1/06 A23L 1/06 1/187 1/187 1/30 1/30 B 2/38 2/38 C 2/52 A61K 7/00 K A61K 7/00 W 7/02 P 7/02 7/06 7/06 7/075 7/075 7/08 7/08 7/26 7/26 7 / 48 7/48 7/50 7/50 9/20 9/20 A61P 17/00 A61P 17/00 37/08 37/08 43/00 113 43/00 113 A23L 2/00 F Int.Cl. 7 , DB name) A61K 35/78 A23C 9/13 A23G 3/00 A23G 9/00 A23L 1/06 A23L 2/38 A23L 2/52 A61K 7/00 A61K 9/20 BIOSIS (DIALOG) CA (STN) MEDLINE (STN)
Claims (8)
酸分解阻止剤。1. A hyaluronic acid decomposition inhibitor comprising a tea extract as an active ingredient.
による抽出物である請求項第1項記載のヒアルロン酸分
解阻止剤。2. The hyaluronic acid decomposition inhibitor according to claim 1, wherein the bean tea extract is an extract using a mixed solvent of water and a polar solvent.
5%含有する請求項第1項または第2項記載のヒアルロ
ン酸分解阻止剤。3. The extract of bean tea from 0.01 to 0.01% by dry weight.
The hyaluronic acid decomposition inhibitor according to claim 1 or 2, which contains 5%.
3項の何れかの項記載のヒアルロン酸分解阻止剤。4. The hyaluronic acid decomposition inhibitor according to any one of claims 1 to 3, which is a lozenge.
3項の何れかの項記載のヒアルロン酸分解阻止剤。 5. The food additive according to claim 1, which is a food additive.
Item 4. The hyaluronic acid degradation inhibitor according to any one of Items 3 to 3.
ーグルト、アイスクリーム、プディング、ゼリー、水よ
うかん、コーヒー飲料、ジュース、炭酸飲料、清涼飲料
水、牛乳、乳清飲料および乳酸菌飲料からなる群より選
ばれたものである請求項第5項記載のヒアルロン酸分解
阻止剤。6. The food to be added is a group consisting of candy, troche, gum, yogurt, ice cream, pudding, jelly, mizuyokan, coffee drink, juice, carbonated drink, soft drink, milk, whey drink and lactic acid drink. The hyaluronic acid degradation according to claim 5, which is selected from the group consisting of:
Inhibitor .
記載のヒアルロン酸分解阻止剤を含有する化粧品。7. A cosmetic comprising the hyaluronic acid degradation inhibitor according to any one of claims 1 to 3.
ーション、口紅、整髪料、ヘアトニック、育毛料、歯磨
き、洗口液、シャンプー、リンスおよび入浴剤からなる
群より選ばれたものである請求項第7項記載の化粧品。8. The method according to claim 1, which is selected from the group consisting of a lotion, a cosmetic cream, a milky lotion, a foundation, a lipstick, a hairdressing agent, a hair tonic, a hair growth agent, a toothpaste, a mouthwash, a shampoo, a rinse and a bath salt. Item 8. The cosmetic according to item 7.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26906896A JP3241610B2 (en) | 1996-09-20 | 1996-09-20 | Pharmaceuticals containing bean tea extract as an active ingredient, and foods and cosmetics containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26906896A JP3241610B2 (en) | 1996-09-20 | 1996-09-20 | Pharmaceuticals containing bean tea extract as an active ingredient, and foods and cosmetics containing the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3023826A Division JP2700958B2 (en) | 1991-01-25 | 1991-01-25 | Pharmaceuticals containing bean tea extract as an active ingredient, and foods and cosmetics containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09118627A JPH09118627A (en) | 1997-05-06 |
JP3241610B2 true JP3241610B2 (en) | 2001-12-25 |
Family
ID=17467218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP26906896A Expired - Lifetime JP3241610B2 (en) | 1996-09-20 | 1996-09-20 | Pharmaceuticals containing bean tea extract as an active ingredient, and foods and cosmetics containing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3241610B2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10324615A (en) * | 1997-05-21 | 1998-12-08 | Pola Chem Ind Inc | Discrimination of cosmetic for pollinosis |
JP3487739B2 (en) * | 1997-08-19 | 2004-01-19 | ポーラ化成工業株式会社 | Cosmetic for hay fever |
EP1761271B1 (en) * | 2004-06-18 | 2008-12-03 | Symrise GmbH & Co. KG | Blackberry extract |
WO2007063087A1 (en) * | 2005-12-02 | 2007-06-07 | Symrise Gmbh & Co. Kg | Blackberry leaf extract as an active ingredient against skin irritations and inflammations |
JP6207692B1 (en) * | 2016-08-15 | 2017-10-04 | アサヒビール株式会社 | Pinene conversion composition, pinene-containing flavor composition, and products containing these |
CN111771976B (en) * | 2020-07-31 | 2023-06-23 | 广西壮族自治区水牛研究所 | Yoghurt with multiple functional activities and preparation method and application thereof |
-
1996
- 1996-09-20 JP JP26906896A patent/JP3241610B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH09118627A (en) | 1997-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11026441B2 (en) | Avocado flesh and/or skin extract rich in polyphenols and cosmetic, dermatological and nutraceutical compositions comprising same | |
US8652543B2 (en) | Cosmetic and/or pharmaceutical compositions and their applications | |
CN113694115A (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
JPWO2005072684A1 (en) | Maca extract manufacturing method | |
JP2700958B2 (en) | Pharmaceuticals containing bean tea extract as an active ingredient, and foods and cosmetics containing the same | |
US20090269424A1 (en) | Peripheral blood flow-improving composition | |
TW201225989A (en) | Sugar-free pineapple extract, production method thereof, and application thereof | |
JPH0853360A (en) | Histamine liberation inhibitor and cosmetic and food product containing the same | |
JP3241609B2 (en) | Pharmaceuticals containing bean tea extract as an active ingredient, and foods and cosmetics containing the same | |
KR20150050310A (en) | Composition for improving skin conditions comprising artemisiae annuae herba, neem leaf, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
KR101889793B1 (en) | Composition for prevention of hair loss or for promoting hair growth comprising a marine animal fermentation | |
JPH0710768A (en) | Hyaluronidase inhibitor containing extract of plant belonging to family leguminosae as active ingredient | |
JP6096943B2 (en) | Food and beverage composition | |
JP3241610B2 (en) | Pharmaceuticals containing bean tea extract as an active ingredient, and foods and cosmetics containing the same | |
JP4672269B2 (en) | Anti-aging agent, platelet aggregation inhibitor, antioxidant, antiallergic agent, skin cosmetics and food and drink | |
EP3205346B1 (en) | Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract | |
JPH06329545A (en) | Hyaluronidase inhibitor containing galenical extract as active ingredient | |
JP2001316275A (en) | Collagen production promoter, estrogen-like agent, collagenase inhibitor, skin cosmetic, food and drink | |
JP4247091B2 (en) | Skin anti-aging agent | |
KR102142461B1 (en) | Composition for improving skin condition comprising extract of korean fir | |
JPH0710765A (en) | Hyaluronidase inhibitor containing extract of plant belonging to family anacardiaceae as active ingredient | |
JPH06329544A (en) | Hyaluronidase inhibitor | |
KR101510939B1 (en) | Composition containing extracts of wheat bran as an active ingredient for preventing of hair loss or for promoting hair growth | |
JP5689247B2 (en) | Ceramide production promoter and moisturizer | |
KR100395932B1 (en) | Skin cosmetic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071019 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081019 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091019 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091019 Year of fee payment: 8 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091019 Year of fee payment: 8 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101019 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111019 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111019 Year of fee payment: 10 |